2019
DOI: 10.1002/bab.1723
|View full text |Cite
|
Sign up to set email alerts
|

Production of a novel N‐terminal PEGylated crisantaspase

Abstract: Crisantaspase is an asparaginase enzyme produced by Erwinia chrysanthemi and used to treat acute lymphoblastic leukemia (ALL) in case of hypersensitivity to Escherichia coli L-asparaginase (ASNase). The main disadvantages of crisantaspase are the short half-life (10 H) and immunogenicity. In this sense, its PEGylated form (PEG-crisantaspase) could not only reduce immunogenicity but also improve plasma half-life. In this work, we developed a process to obtain a site-specific N-terminal PEGylated crisantaspase (… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
3
0
4

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 22 publications
1
3
0
4
Order By: Relevance
“…There are three forms of treatment for ALL using Lasparaginase in clinical practice: the native enzyme derived from Escherichia coli, the pegylated enzyme, and an isolated ASNase from Erwinia chrysanthemi [6][7][8]. Treatment with bacterial L-asparaginase has produced some important side effects, such as neurological crisis, anaphylaxis, coagulation disorders, leukopenia, thrombosis, pancreatitis, hyperglycemia, and hepatotoxicity [2].…”
Section: Introductionmentioning
confidence: 99%
“…There are three forms of treatment for ALL using Lasparaginase in clinical practice: the native enzyme derived from Escherichia coli, the pegylated enzyme, and an isolated ASNase from Erwinia chrysanthemi [6][7][8]. Treatment with bacterial L-asparaginase has produced some important side effects, such as neurological crisis, anaphylaxis, coagulation disorders, leukopenia, thrombosis, pancreatitis, hyperglycemia, and hepatotoxicity [2].…”
Section: Introductionmentioning
confidence: 99%
“…Tabela 2. Características dos principais biofármacos de L-asparaginase in vivo (OBREQUE, 2017). Por outro lado, a L-asparaginase nativa de E. coli é a opção que apresenta maior afinidade ao substrato, embora requeira maiores dosagens e atenções com efeitos alergênicos.…”
Section: L-asparaginase E Leucemia Linfoblástica Agudaunclassified
“…A etapa de extração consiste na retirada da L-asparaginase que, neste caso, é encontrada tanto no citoplasma como no espaço periplasmático, não sendo a enzima transportada para o meio extracelular (Torres-Obreque et al, 2019).…”
Section: Seção De Downstreamunclassified
See 2 more Smart Citations